FindTrial
Sign In

The Prescribing Patterns of Edoxaban15mg for Very Elderly Non-Valvular Atrial Fibrillation (NVAF) Patients in Japan.

The Prescribing Patterns of Edoxaban15mg for Very Elderly Non-Valvular Atrial Fibrillation (NVAF) Patients in Japan. - The Prescribing Patterns of Edoxaban15mg for Very Elderly Non-Valvular Atrial Fibrillation (NVAF) Patients in Japan.

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000055684
Enrollment
Unknown
Registered
2024-10-02
Start date
2024-09-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Valvular Atrial Fibrillation

Interventions

None listed

Sponsors

Daiichi Sankyo Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Jan.2019-Dec.2023 Include patients who meet all of the following conditions. 1.Patients aged 80 years and older. 2.Patients with an ICD10 code for atrial fibrillation.

Exclusion criteria

Exclusion criteria: Exclude patients who meet any of the following conditions. 1.Patients with diagnosis of valvular atrial fibrillation, chronic rheumatic heart disease. 2.Patients with history of mechanical heart valves. 3.Patients with diagnosis of deep vein thrombosis and pulmonary thromboembolism 4.Patients with history of total knee replacement, total hip replacement and hip fracture surgery.

Design outcomes

Primary

MeasureTime frame
To observe the characteristics (bleeding risk factor, etc) of patients prescribed edoxaban15mg for elderly NVAF.—

Countries

Japan

Contacts

Public ContactMasako Sugimoto

Daiichi Sankyo Co., Ltd. Primary Medical Science Department

masako.sugimoto@daiichisankyo.com03-6225-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026